Loading patent…
AssigneesAjinomoto Co., Inc., Kazuo Sugamura
InventorsToshiro Shimamura, Junji Hamuro, Harumi Nakazawa, Yuka Kanayama, Kazuo Sugamura, Toshikazu Takeshita
Estimating the term…
A polypeptide which specifically binds to the .gamma.-chain of the human interleukin-2 receptor and selectively inhibits the binding of the .gamma.-chain of human interleukin-2 receptor to the .beta.-chain of the same is provided. The polypeptide has an activity of blocking the human interleukin-2 response. Also provided are an immunosuppressant containing the polypeptide, a DNA gene coding for the polypeptide, a recombinant DNA having the gene, a transformant having the recombinant DNA, and a method for producing the intended polypeptide by incubating the transformant. The novel polypeptide can be used independently, or with substances capable of inhibiting the binding of interleukin-2 to the interleukin-2 receptor, as a medicine for preventing the rejection of grafts after transplantation and also for curing inflammatory diseases such as allergic diseases and autoimmune diseases.
A DNA coding for a polypeptide which specifically binds to the .gamma.-chain of human interleukin-2 receptor, therefore having an activity of blocking the human interleukin-2 response.
An immunosuppressant composition comprising a carrier and a therapeutically effective amount of
Dependencies are inferred from the claim text.